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Inflammatory cytokines are well-recognized media-
tors of atherosclerosis. Depending on the patholog-
ical context, type I interferons (IFNs; IFNa and IFNb)
exert either pro- or anti-inflammatory immune func-
tions, but their exact role in atherogenesis has not
been clarified. Here, we demonstrate that IFNb
enhances macrophage-endothelial cell adhesion
and promotes leukocyte attraction to atheroscle-
rosis-prone sites in mice in a chemokine-dependent
manner.Moreover, IFNb treatment accelerates lesion
formation in two different mouse models of athero-
sclerosis and increases macrophage accumulation
in the plaques. Concomitantly, absence of endoge-
nous type I IFN signaling in myeloid cells inhibits
lesion development, protects against lesional accu-
mulation of macrophages, and prevents necrotic
core formation. Finally, we show that type I IFN
signaling is upregulated in ruptured human athero-
sclerotic plaques. Hereby, we identify type I IFNs as
proatherosclerotic cytokines that may serve as addi-
tional targets for prevention or treatment.
INTRODUCTION
The important contribution of inflammatory cytokines to athero-
sclerosis development is well recognized (Hansson and Libby,
2006; Tedgui and Mallat, 2006; Weber et al., 2008). The macro-
phage is both an important source and a major target of these
inflammatory mediators. Specific cytokines influence macro-
phage effector functions and thereby affect plaque initiation,142 Cell Metabolism 12, 142–153, August 4, 2010 ª2010 Elsevier Incprogression, and cellular composition. Ultimately, macrophages
hereby alter important plaque stability factors such as necrotic
core formation and inflammatory cell content. Hence, themacro-
phage is a very attractive target for designing therapeutic inter-
ventions (Li and Glass, 2002), making it crucial to understand
how cytokines regulate macrophage function in atherogenesis.
Cytokines of the type I interferon (IFN) family (IFNa and IFNb)
are produced by immune cells in response to pathogenic
challenges such as viruses, bacteria, and tumor cells. They
induce antiviral responses (Borden et al., 2007; Katze et al.,
2002), have immunomodulating activities, and are clinically
used to treat viral diseases, multiple sclerosis, and certain
tumors (Borden et al., 2007; Paty and Li, 1993; Takaoka and
Yanai, 2006). Recent data indicate that IFNb is also necessary
for sustaining TNF-driven inflammation (Yarilina et al., 2008),
promotes TNF-induced lethal shock (Huys et al., 2009), and
mediates MHC-I induction by TNF (Leeuwenberg et al., 1987).
In addition, constitutive low levels of type I IFN amplify
IFNg- and interleukin-6 (IL-6)-driven inflammatory responses
(Mitani et al., 2001; Takaoka et al., 2000). Thus, type I IFNs
also modulate immune responses that are not directly induced
by pathogens. In sharp contrast to the clinical application of
IFNb as treatment for the pathologies mentioned above, type I
IFNs have also been shown to promote disease in systemic
lupus erythematosus (SLE), where inhibition strategies are being
considered for therapy (Ro¨nnblom et al., 2006). Of interest, it was
recently postulated that the increased risk of cardiovascular
mortality in SLE patients (McMahon and Hahn, 2007) is linked
to their elevated levels of type I IFNs (Lee et al., 2007). Thus,
depending on the context, type I IFN may have either disease-
promoting or disease-inhibiting properties.
The important immunomodulatory activities of type I IFNs
prompted us to hypothesize that they also have a role in athero-
genesis. We show that IFNb treatment induces chemokine-
dependent adhesion and migration of leukocytes and promotes.
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Type I IFN in Atherosclerosisatherosclerosis development in vivo. Consequently, we show
that inhibition of type I IFN signaling in myeloid cells hampers
cellular recruitment to lesions and thus atherosclerosis develop-
ment. Finally, we found that type I IFN signaling is an integral
feature of human atherosclerosis as well and is upregulated in
plaque instability.
RESULTS
IFNb Treatment of Macrophages Induces Chemotactic
Factors
To study the effect of type I IFN on macrophages, we first
performed in vitro studies with cultured bone marrow-derived
macrophages (BMM) and analyzed cytokine secretion, uptake
pathways, and factors mediating adhesion and migration.
Though TNF and IL-12 were not induced by IFNb, treatment
did induce the expression of the anti-inflammatory cytokine
IL-10 (Figure 1A). Next, we analyzed uptake pathways by BMM
that had been pretreated with IFNb. Neither endocytosis of
oxidatively modified LDL (oxLDL) nor phagocytosis of fluores-
cently labeled latex beads was affected by treatment of cells
with IFNb (Figures 1B and 1C). We further focused on molecules
mediating attraction of cells to atherosclerotic lesions. FACS
analysis of IFNb-treated macrophages showed no differences
for any of the major integrins necessary for rolling and arrest at
inflammatory sites (Figure 1D). Of interest, gene expression of
the chemokine and chemokine receptors (Figures 1E and 1F)
CCL5 (RANTES) and its receptor CCR5, as well as CCR2, was
upregulated in macrophages activated with IFNb. However,
further FACS analysis showed no significant upregulation of
surface expression of both CCR2 and CCR5 (Figure 1G). In
contrast, CCL5 secretion was strongly increased by activation
of macrophages with IFNb (Figure 1H). Next, we studied the
role of the main receptor for type I IFN, IFNAR1, and for this,
macrophages from mice with a myeloid-specific deletion of
IFNAR1 (Prinz et al., 2008) were used. Quantitative PCR showed
a deletion efficiency of IFNAR1 of 73.2% ± 1.4%, and CCL5
induction by IFNb was reduced to a similar extent in IFNAR1-
deleted cells (IFNAR1del) compared to control cells (IFNAR1WT)
(Figure 1I). Ablation of signal transducer and activator of tran-
scription 1 (STAT1) signaling, as a key downstream transcription
factor of type I IFN signaling, almost completely abolished induc-
tion of CCL5 by IFNb (Figure 1J). CCL5 ELISA showed similar
reduction in secreted CCL5 for IFNAR1del and STAT1/ cells
(Figure S1 available online). Treatment of macrophages with
another type I IFN, IFNa, showed comparable effects on CCR5
and CCL5 (Figure S2). Thus, in addition to inducing IL-10,
type I IFN treatment of primary macrophages induces chemo-
tactic factors, which may influence leukocyte attraction and
atherosclerosis development.
IFNb Treatment Enhances In Vitro Macrophage
Adhesion and Promotes In Vivo Leukocyte Arrest
In line with our data described above, we found that static
adhesion of IFNb-treated macrophages to endothelial cells
was enhanced (Figure 2A). Endothelial adhesion of macro-
phages lacking IFNAR1 or STAT1 was not inducible by IFNb
(Figures 2B and 2C). In line with a major role for CCL5-CCR5
signaling, we found that IFNb-induced adhesion was notCelaffected in CCR1-deficient macrophages but was completely
blunted in macrophages lacking CCR5 (Figure 2D). Absence of
CCR2 showed an intermediate phenotype, with a moderate
effect of IFNb. In vivo, 4 days treatment of high-fat fed apolipo-
protein E-deficient (apoe/) mice with IFNb led to a strong
increase of leukocyte arrest in the carotid arteries of these
animals (Figure 2E). Cotreatment of mice with the CCL5 antago-
nist Met-Rantes just prior to analyzing leukocyte arrest reduced
leukocyte arrest in untreated mice and fully restored leukocyte
adhesion to control levels in IFNb-treated animals (Figure 2E).
Thus, IFNb treatment in vitro and in vivo promotes leukocyte
adhesion and attraction to the endothelium through CCL5-
CCR5-dependent mechanisms.
IFNb Treatment Accelerates Atherogenesis
in apoe/ and ldlr/ Mice
Next, we analyzed the effect of IFNb on atherogenesis in two
well-established mouse models of atherosclerosis. Daily injec-
tions of IFNb in a collar-induced atherosclerosis model in
apoe/ mice (von der Thu¨sen et al., 2001) did not alter plasma
cholesterol levels (27.89 ± 2.10 and 26.98 ± 2.04 mM for the
ctrl and IFNb treated, respectively) but increased plasma levels
of IL-10 (3.90 ± 2.1 and 19.21 ± 5.8 pg/ml, p < 0.05, for the ctrl
and IFNb treated, respectively). Atherosclerotic lesion analysis
(Figures 3A and 3B) showed a strong increase in lesion formation
in mice that had been treated with IFNb. The same effect was
seen in low-density lipoprotein receptor-deficient (ldlr/) mice
in which IFNb treatment increased aortic root atherosclerotic
lesion size by almost 2-fold (Figures 3C and 3D) without any
effects on plasma cholesterol (26.30 ± 1.78 and 26.86 ± 1.66
for the ctrl and IFNb treated, respectively) or blood leukocyte
levels (B220+ B cells, CD3+ T cells, Gr1hiCD11b+ neutrophils,
and Gr1int/-CD11b+ monocytes; data not shown). Staining for
macrophage content showed an 2-fold increase in absolute
macrophage area in IFNb-treated mice (Figures 3E and 3F).
Gene expression analysis of aortic arches from these mice
also showed increased expression of the macrophage marker
CD68 (Figure 3G), further indicating increased macrophage
accumulation in atherosclerotic lesions. More extensive immu-
nohistochemical analysis of the aortic root lesions did not
show any significant difference with respect to neutrophil or
T cell accumulation, TUNEL-positive cells, or necrotic core
formation (data not shown). Of interest, we did find an induction
of circulating CCL5 levels in IFNb-treatedmice (Figure 3H). Thus,
despite the induction of IL-10, IFNb treatment enhances athero-
sclerosis development, coinciding with increased levels of
CCL5.
Myeloid IFNAR1 Deletion Reduces Atherosclerosis
Development
Subsequently, we investigated whether endogenous production
of type I IFN also contributes to atherosclerosis development.
We first analyzed whether typical type I IFN signature genes
were expressed in lesions of atherosclerotic mice. Indeed,
expression of OAS1, OAS2, MX2, and IRF9 could be readily de-
tected in aortic arches from ldlr/mice that had been fed a high-
fat diet for 6 or 9 weeks (Figure S3), indicating that endogenous
type I IFN signaling is present. We then performed a transplanta-
tion using bone marrow from IFNAR1WT and IFNAR1del mice,l Metabolism 12, 142–153, August 4, 2010 ª2010 Elsevier Inc. 143
Figure 1. The Effect of IFNb on Cultured Bone Marrow-Derived Macrophages
(A) Treatment of macrophages with IFNb induces IL-10 expression without affecting TNF or IL-12.
(B) Uptake of DiI-labeled oxLDL by control (ctrl)- or IFNb-treated macrophages.
(C) Uptake of fluorescent latex beads by ctrl- or IFNb-treated macrophages.
(D) Surface expression of VLA-4, Mac1, LFA-1, and PSGL1 in ctrl- or IFNb-treated macrophages.
(E) Relative gene expression of chemokine receptors in ctrl- or IFNb-treated macrophages.
(F) Chemokine expression after IFNb treatment of macrophages.
(G) FACS analysis of CCR2 and CCR5 after treatment with IFNb.
(H) CCL5 secretion by macrophages after treatment with IFNb.
(I) CCL5 expression in ctrl- and IFNb-stimulated IFNAR1WT and IFNAR1del macrophages.
(J) CCL5 expression in ctrl- or IFNb-treated wild-type and STAT1/ macrophages.
Graphs are representative for at least two independent experiments. Bars represent mean of triplicate wells ± SEM. *p < 0.05, **p < 0.01.
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Type I IFN in Atherosclerosisspecifically lacking IFNAR1 in their myeloid lineage, to ldlr/
mice to yield atherosclerosis-susceptible mice that were either
wild-type (IFNAR1WT) or deleted (IFNAR1del) for IFNAR1 in their
myeloid cells. Compared with IFNAR1WT mice, mice lacking
myeloid IFNAR1 showed a strong reduction in atherosclerotic144 Cell Metabolism 12, 142–153, August 4, 2010 ª2010 Elsevier Inclesion size (34%) (Figures 4A and 4B) after 11 weeks of high-
fat diet. Lesions were mainly composed of macrophages
(Figure 4C), and absolute macrophage area in the lesions was
reduced in the IFNAR1del mice (Figure 4D). Furthermore, the
lesions were of intermediate phenotype, consisting mainly of.
Figure 2. IFN Affects Static In Vitro Adhesion and In Vivo Leukocyte Arrest
(A) Adhesion of untreated macrophages (ctrl) to endothelial cells compared to IFNb-treated macrophages (**p < 0.01).
(B) Adhesion of ctrl- or IFNb-treated IFNAR1WT and IFNAR1del macrophages (*p < 0.05).
(C) Adhesion of ctrl- or IFNb-treated wild-type or STAT1/ macrophages (**p < 0.01).
(D) Adhesion of ctrl- or IFNb-treated CCRwild-type, CCR1/,CCR2/, or CCR5/macrophages, all on an apoe/ background (*p < 0.05, **p < 0.01). All bars
for in vitro adhesion represent mean of triplicate wells ± SEM; stars indicate significant differences compared to ctrl-treated cells of the same genotype.
(E) Leukocyte arrest in the carotid artery of apoe/ mice (ctrl), after treatment with Met-Rantes (ctrl+Met-Rantes), after 4 days IFNb treatment (IFNb), or after
4 days IFNb treatment combined with Met-RANTES treatment (IFNb+Met-Rantes). n = 8, 4, 7, and 5 for the four groups, respectively.
Error bars indicate SEM. *p < 0.05 or **p < 0.01 compared to ctrl; #p < 0.01 compared to IFNb.
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Type I IFN in Atherosclerosismacrophage-derived foam cells with a fibrotic cap and some
necrosis. IFNAR1del mice showed reduced numbers of ad-
vanced lesions and increased numbers of moderate and early
lesions (Figure 4E).
Plasma cholesterol levels did not differ between groups just
before the start of the diet and after high-fat feeding (Figure 4F).
In addition, total leukocyte counts (Figure 4G) and blood levels of
leukocyte subsets (Figure 4H) did not differ between IFNAR1WT
and IFNAR1del mice. Plasma cytokine levels were reduced,
with a strong reduction (70%) of circulating IL-6 (Figure S3)
and a borderline (p = 0.05) reduction of the chemokine CCL2
(MCP-1) in IFNAR1del mice.
Further examination of the lesions showed the neutrophil
content to be decreased in atherosclerotic lesions of IFNAR1del
mice (Figures 5A and 5B), whereas T cell content did not differ
(Figure 5C). Because type I IFNs have been implicated in the
regulation of cell survival and proliferation (Borden et al., 2007),
cell proliferation and apoptosis were assessed by Ki-67 and
TUNEL staining, but no differences were observed between
the two groups (Figures 5D and 5E). We did, however, find
a strong (>70%) reduction of necrosis in the lesions of IFNAR1del
mice (Figures 5F and 5G), which is often considered a plaque-
destabilizing consequence of impaired efferocytosis in the
lesions (Tabas, 2005). Thus, endogenously produced type I
IFNs activate myeloid cells, increase lesional accumulation of
macrophages and neutrophils, promote necrotic core formation,
and thereby promote atherosclerosis development.CelIFNb Induces Chemotactic Factors in Human
Macrophages, and IFN Signaling Is Upregulated
in Ruptured Human Atherosclerotic Lesions
To investigate whether type I IFNs also play a role in the patho-
genesis of human atherosclerosis, we first analyzed the effect
of IFNb on primary human macrophages. Although IFNb did
not induce CCR2 (Figure 6A), it did increase expression of both
CCR5 and CCL5 (Figures 6B and 6C) and induced secretion of
CCL5 as analyzed by ELISA (Figure S4), confirming our mouse
data. Next, Ingenuity Pathway Analysis was performed on an
expression database of human atherosclerotic lesions. We
compared data from stable carotid endarterectomy specimens
and ruptured specimens, which had been classified according
to the Virmani classification (Virmani et al., 2000). Of interest,
the type I IFN pathway showed a highly significant upregulation
in ruptured lesions when compared to stable lesions (Figure 6D).
In addition to the upregulation of the type I IFN pathway, several
chemotactic factors including CCR5 and CCL5 were also upre-
gulated in ruptured atherosclerotic lesions (Table S1). These
data show that upregulation of type I IFN signaling correlates
with plaque rupture in human atherosclerosis.
DISCUSSION
In this paper, we show that treatment with IFNb enhances
atherogenesis in different models and that myeloid-specific
inhibition of type I IFN signaling reduces atherosclerosisl Metabolism 12, 142–153, August 4, 2010 ª2010 Elsevier Inc. 145
Figure 3. IFNb Treatment Accelerates Atherosclerosis in apoe/ and ldlr/ Mice
(A) Representative lesions of ctrl- or IFNb treated mice of collar-induced atherosclerosis in apoe/ mice. Scale bar, 50 mm.
(B) Lesion area measured at six sequential locations proximal from the collar in apoe/ mice that were ctrl or IFNb treated. **p < 0.01 by two-way ANOVA;
n = 9/12.
(C) Representative lesions in the aortic root of ctrl- or IFNb-treated ldlr/ mice. Scale bar, 200 mm.
(D) Lesion area at the aortic root of ctrl- or IFNb-treated ldlr/ mice. *p < 0.05; n = 12/14.
(E) Representative MOMA-2-stained lesions from ctrl- and IFNb-treated ldlr/ mice. Scale bar, 100 mm.
(F) Absolute macrophage area in lesions from ctrl- or IFNb-treated ldlr/ mice. *p < 0.05; n = 12/14.
(G) CD68 expression in aortic arches from ctrl- or IFNb-treated ldlr/ mice. **p < 0.01; n = 11/14.
(H) CCL5 levels in plasma from ctrl- or IFNb-treated ldlr/ mice. **p < 0.01; n = 9/11.
Shown are mean ± SEM.
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Type I IFN in Atherosclerosisdevelopment. We demonstrate that IFNb treatment induces
chemotactic factors and thereby promotes leukocyte attraction
to atherosclerosis-prone sites. Accordingly, absence of endog-
enous myeloid type I IFN signaling reduced accumulation of146 Cell Metabolism 12, 142–153, August 4, 2010 ª2010 Elsevier Inccells from the myeloid lineage in the lesions. Thus, type I
IFNs are proatherosclerotic cytokines that act by promoting
chemokine-dependent leukocyte recruitment to atherosclerotic
lesions. Of interest, upregulation of type I IFN signaling is.
Figure 4. Absence of Myeloid IFNAR1 Reduces Atherosclerosis Development
Bone marrow from conditional mice devoid of IFNAR1 only on myeloid cells was transplanted to ldlr/mice to yield atherosclerosis-susceptible mice that were
either wild-type (IFNAR1WT) or deleted (IFNAR1del) for IFNAR1 in their myeloid cells.
(A) Representative toluidin blue-stained lesions from IFNAR1WT and IFNAR1del mice. Scale bar, 200 mm.
(B) Lesion area at the aortic root of IFNAR1WT and IFNAR1del mice. **p < 0.01; n = 19/15.
(C) Representative MOMA-2-stained lesions from IFNAR1WT and IFNAR1del mice. Scale bar, 100 mm.
(D) Absolute macrophage area in lesions from IFNAR1WT and IFNAR1del mice. *p < 0.05; n = 17/14.
(E) Lesion severity in IFNAR1WT and IFNAR1del mice. p < 0.05 by Chi-square test; n = 19/15.
(F) Plasma cholesterol levels before (chow) and after 8 weeks of high-fat diet (HFD) in IFNAR1WT and IFNAR1del transplanted mice.
(G and H) Total leukocyte counts and relative levels of leukocyte subsets.
Shown are mean ± SEM.
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Type I IFN in Atherosclerosisalso associated with plaque rupture in human atherosclerotic
lesions.
The family of type I IFNs consists of many members, with IFNa
and IFNb being the most abundant and best studied. It was
previously shown that IFNa treatment promotes atherosclerosisCelin ldlr/ mice. However, this effect was accompanied by
elevated plasma levels of triglycerides and cholesterol (Levy
et al., 2003), which complicates the interpretation of these
data. Therefore, we chose to use IFNb in our treatment studies,
although we found that IFNa had similar in vitro effects onl Metabolism 12, 142–153, August 4, 2010 ª2010 Elsevier Inc. 147
Figure 5. Absence of Myeloid IFNAR1 Influences the Phenotype of Atherosclerotic Lesions
(A) Representative NIMP stainings of lesions from IFNAR1WT and IFNAR1del mice. Scale bar, 50 mm.
(B) Neutrophil influx in lesions from IFNAR1WT and IFNAR1del mice. *p < 0.05.
(C–E) T cells, proliferation, and apoptosis in lesions from IFNAR1WT and IFNAR1del mice.
(F) Representative examples of necrosis in lesions from IFNAR1WT and IFNAR1del mice. Scale bar, 50 mm.
(G) Necrosis in lesions from IFNAR1WT and IFNAR1del mice. **p < 0.001. For all analyses, n = 19 and 15 for IFNAR1WT and IFNAR1del mice, respectively.
Shown are mean ± SEM.
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Type I IFN in Atherosclerosischemotactic factors. Zhang et al. describe that IFNb administra-
tion attenuates lesion formation induced by carotid artery liga-
tion in angiotensin II-infused apoe/ mice (Zhang et al., 2008),
which is in contrast to our findings. Thus, angiotensin accelera-
tion of atherosclerosis depends on other inflammatory factors
than our models. We now show, using two different models of
atherosclerosis, that IFNb treatment promotes atherosclerosis
in high fat-fed mice. In both a collar-accelerated model (in the
apoe/ mice) and a solely hyperlipidemia-driven model (in the148 Cell Metabolism 12, 142–153, August 4, 2010 ª2010 Elsevier Incldlr/ mice), atherogenesis was enhanced by IFNb without
influencing plasma lipid parameters.
We found that IFNb treatment of isolated primary macro-
phages induced IL-10. In addition, IFNb treatment of mice led
to increased levels of circulating IL-10, as is similarly observed
in MS patients and mouse models for MS (Rudick et al., 1998).
IL-10 is a classical anti-inflammatory cytokine, and the beneficial
effects of IFNb treatment in relapsing remitting MS patients is at
least partly attributed to anti-inflammatory factors that it induces.
Figure 6. IFNb Induces Chemotactic Factors in Human Primary Macrophages, and Type I IFN Signaling Is Upregulated in Ruptured Human
Atherosclerotic Lesions
(A) CCR2 expression in macrophages from two independent donors after IFNb treatment.
(B) CCR5 expression in macrophages from two independent donors after IFNb treatment. *p < 0.05; **p < 0.01.
(C) CCL5 expression in macrophages from two independent donors after IFNb treatment. **p < 0.01. Error bars indicate mean of triplicate wells ± SEM.
(D) Ingenuity Pathway Analysis of the differentially expressed genes in stable compared to ruptured carotid endarterectomy specimens. Red signals indicate
upregulation and the pathway showed a strongly significant (p = 2.36 3 106; ratio 16/23 [0.696]) upregulation of type I IFN signaling. Indicated are the fold
changes (FC) of the respective genes.
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Type I IFN in Atherosclerosis(Billiau, 2006). The induction of this anti-atherogenic (Mallat
et al., 1999) cytokine contrasts with the atherosclerosis-pro-
moting effect that we observe for IFNb. However, we did find
IFNb to specifically elicit chemotactic factors with a reported
proatherogenic function. CCL2 (MCP-1) and CCL5 (RANTES)
and their receptors (CCR2 and CCR5, respectively) are impor-
tant in regulating attraction of cells to atherosclerotic lesions
and thereby control atherosclerosis development (Boring et al.,
1998; Braunersreuther et al., 2007; Veillard et al., 2004). We
found that especially CCL5 was strongly upregulated after
IFNb treatment of macrophages, coinciding with a modestCelinduction of CCR5 and CCR2. CCL5 expression after IFNb was
reduced in macrophages lacking either IFNAR1 or STAT1, indi-
cating that CCL5 is either a direct target of IFNAR1-STAT1
signaling or is regulated by interferon regulatory factors (IRFs)
induced by STAT1 activation (Cremer et al., 2002; Melchjorsen
et al., 2003; Taniguchi and Takaoka, 2001). We could also
show that IFNb increased static adhesion of macrophages to
endothelial cells, again in an IFNAR1- and STAT1-dependent
manner, which was abolished by macrophage CCR5 deficiency,
but not by deficiency for CCR1, the other major receptor for
CCL5. CCR2 deficiency had a modest effect on IFNb-inducedl Metabolism 12, 142–153, August 4, 2010 ª2010 Elsevier Inc. 149
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Type I IFN in Atherosclerosismacrophage adhesion. Furthermore, enhanced leukocyte arrest
induced by IFNb in apoe/ mice could be completely blocked
by cotreatment with the CCL5 receptor inhibitor Met-Rantes. In
line with these findings, we found an induction of circulating
CCL5 in IFNb-treated mice. Moreover, plasma CCL5 analysis
in a small number of mice from the IFNAR1 bone marrow
transplantation showed a trend toward a reduction in IFNAR1del
transplanted ldlr/ mice (95.0 ± 6.9 and 73.5 ± 5.2 pg/ml for
IFNAR1WT and IFNAR1del mice; p = 0.07). Therefore, we think
that, despite the induction of IL-10 by IFNb, the atherosclerotic
process is actually enhanced through the induction of especially
the CCL5-CCR5 axis, thereby promoting attraction of leukocytes
to lesions.
Type I interferons are massively produced by various cell
types in response to viruses and other microbial stimuli through
engagement of toll-like receptors such as TLR3, TLR4, and
TLR9. In search of endogenous triggers that stimulate the inflam-
matory response accompanying atherosclerosis, it was recently
demonstrated that cholesterol crystals can activate the NLRP3
inflammasome and thereby significantly contribute to athero-
genesis (Duewell et al., 2010). Moreover, oxidized LDL was
shown to activate the TRIF pathway by binding to a TLR4/6-
CD36 complex, potentially leading to type I IFN production by
macrophages in lesions (Stewart et al., 2010). Additional major
in vivo sources of type I IFN are plasmacytoid dendritic cells
(pDCs). Of interest, DCs and, more specifically, pDCs have
been identified in human atherosclerotic lesions and have been
associated with rupture-prone areas of the lesions (Bobryshev
and Lord, 1995; Niessner et al., 2006; Yilmaz et al., 2004). Using
data sets from stable and ruptured human endarterectomy
segments, we now show that segments of ruptured plaque
have an upregulation of the type I IFN signaling pathway when
compared to stable segments. Thus, ruptured atherosclerotic
lesions show induction of type I IFN signaling. This may conse-
quently increase attraction of inflammatory cells, further contrib-
uting to matrix degradation and plaque destabilization.
Using conditional knockouts, we demonstrate that myeloid
cells are important targets for endogenously produced type I
IFN in atherosclerosis. Through induction of chemotactic fac-
tors, type I IFN signaling promotes macrophage adhesion to
endothelial cells. As such, deletion of IFNAR1 in myeloid cells
ultimately leads to reduced accumulation of macrophages in
atherosclerotic lesions and thereby reduces atherosclerosis
development. We determined deletion efficiency to be 70%
in our bone marrow cultures, indicating some remaining type I
IFN signaling. In addition, it was previously shown that circulating
monocytes from LysMCre-IFNAR1floxed mice show severely
hampered, but not fully absent, type I IFN signaling (Prinz
et al., 2008). Thus, the phenotype that we observe is likely the
result of reduced, but not completely absent, myeloid type I
signaling. Whether this merely means an underestimation of
the contribution of endogenous type I signaling in atheroscle-
rosis or whether additional functions are therefore undetectable
remains to be discovered.
In addition to affecting macrophages, myeloid IFNAR1 defi-
ciency also reduces accumulation of neutrophils in the lesions,
which have recently been found to contribute to atherosclerosis
(van Leeuwen et al., 2008; Zernecke et al., 2008). Disturbed
macrophage CCL5 production may impair lesional recruitment150 Cell Metabolism 12, 142–153, August 4, 2010 ª2010 Elsevier Incof neutrophils, which use CCR1 to respond to CCL5 (Liehn et al.,
2008). Alternatively, IFNAR1 deficiency may have unexplored
direct effects on neutrophils influencingmigration to inflammatory
sites. However, in our treatment approach with ldlr/ mice,
neutrophil accumulation in the lesions was not affected (data not
shown), indicating that IFNb treatment does not affect neutrophils
in these studies. In addition, although we clearly identify that
myeloid IFNAR1 signaling highly controls lesion development,
we cannot exclude that other targets of type I IFN, such as endo-
thelial cells or fibroblasts, will contribute to the effects that we
observe upon treatment of the mice with IFNb.
We found that inhibition of endogenous myeloid type I IFN
signaling reduces necrotic core formation and thus directly
affects plaque stability. Reduced necrosis paralleled impaired
progression of the lesions. However, upon analysis of a subset
of lesions from both groups with similar size (84.5 ± 4.8 and
81.4 ± 4.2 3 1000 mm2 for the IFNAR1WT and IFNAR1del groups)
and severity (moderate lesions), we found that necrotic core
formation was still reduced in the IFNAR1del group (12.6% ±
2.4%and 4.0%±1.3% for the IFNAR1WT and IFNAR1del groups).
Thus, inhibition of myeloid IFNAR1 function directly inhibits
necrotic core formation independent of lesion size and severity
and without any clear effects on endocytosis or phagocytosis.
Depending on the experimental context, both pro- and anti-cell
death functions have been attributed to type I IFN. The antitumor
effects of type I IFN are at least partly attributed to the induction
of cell death by type I IFN (Borden et al., 2007), in which IFNs and
interferon-stimulated genes are both sensitizing tumor cells to
immune cell-mediated cytotoxicity and augmenting lytic activity
of immune cells. In line with this, several groups have reported
that endogenous type I interferon signaling sensitizes cells to
pathogen-induced cell death (O’Connell et al., 2004; Qiu et al.,
2008) or apoptosis induced by serum deprivation (Wei et al.,
2006). In addition, treatment ofMS patients with IFNbwas shown
to prime monocyte-derived macrophages for apoptotic cell
death (Van Weyenbergh et al., 2001). We show that inhibition
of myeloid type I IFN signaling reduces necrosis, but treatment
of ldlr/ mice with IFNb did not enhance necrotic core forma-
tion. Thus, in atherogenesis, the necrosis-promoting effect of
endogenous type I IFN is apparently already maximal and not
further promoted by exogenously added IFNb.
Our findings are supported by previous studies demonstrating
that type I IFNs are important inducers of cellular migration. The
attraction of inflammatory cells is an important feature of type I
IFN action in fighting microbial infections (Borden et al., 2007).
In addition, it was recently shown that type I IFNs are also essen-
tial mediators of TNF-induced lethal inflammatory shock by
enhancing cell death and promoting white blood cell influx in
tissues through induction of a set of chemokines (Huys et al.,
2009). Moreover, in search of IFNb-related adverse side effects
in MS patients, several groups performed gene expression
studies on peripheral blood mononuclear cells and demon-
strated induction of chemotactic factors in response to IFNb
treatment (Satoh et al., 2006; Wandinger et al., 2001). In line
with this, it was recently shown that a group of chemotactic
genes, including CCL5 and CCL2, was among those most
prominently upregulated in brain macrophages (microglia)
treated with IFNb (Prinz et al., 2008). We focused on the major
chemokines and chemokine receptors with a demonstrated.
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Type I IFN in Atherosclerosisrole in atherogenesis and found that especially the CCL5-CCR5
axis may be very important in mediating the proatherogenic
function of IFNb.
In conclusion, we show that type I IFNs promote atheroscle-
rosis development. Contrary to the antiviral effect of type I IFN
acting on a multitude of cell types, we report that the specific
interaction of endogenous type I IFNwithmyeloid cells enhances
the recruitment of these cells to atherosclerotic lesions. This
effect is in accordance with the type I IFN-induced macrophage
adhesion mediated by upregulation of specific chemokines
and their receptors, mainly involving the CCL5-CCR5 axis.
Furthermore, we present plaque destabilizing necrotic core
formation as a direct consequence of myeloid type I IFN
signaling. Collectively, these data raise the demand for further
detailed analyses of cardiovascular risk in patients treated with
type I IFN and may even imply that caution should be taken in
using type I IFN as a therapeutic option. In contrast, targeting
of type I IFN signaling may be an attractive target for prevention
and treatment of atherosclerosis.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 mice and ldlr/ mice on a C57BL/6 background were obtained
from Jackson Laboratory (Bar Harbor, ME), and apoe/ mice on a C57BL/6
background were obtained from Iffa Credo (Lyon, France). IFNAR1fl/fl, LysM-
Cre-IFNAR1fl/fl, apoe/, apoe/CCR1/, apoe/CCR2/, apoe/
CCR5/, and STAT1/ mice were all on a C57BL/6 background and have
been described before (Durbin et al., 1996; Prinz et al., 2008; Schober et al.,
2004; Zernecke et al., 2006). All animal experiments were approved by the
Committee for Animal Welfare of the Maastricht University or complied with
German animal protection law.
Interferons
Recombinant murine IFNa or IFNb were obtained from Hycult Biotech (Uden,
The Netherlands). Human IFNb was obtained from Peprotech (Rocky Hill, NJ).
In Vitro Murine Macrophage Culture
Bone marrow cells were isolated from femurs and tibiae of wild-type mice
(C57BL/6), IFNAR1fl/fl, LysMCre-IFNAR1fl/fl, apoe/, apoe/CCR1/,
apoe/CCR2/, apoe/CCR5/, or STAT1/ mice. Cells were cultured
in RPMI-1640 (GIBCO Invitrogen, Breda, The Netherlands) with 10% heat-in-
activated fetal calf serum (Bodinco B.V., Alkmaar, The Netherlands), penicillin
(100U/ml), streptomycin (100 ug/ml), and L-glutamine 2mM (all GIBCO Invitro-
gen, Breda, The Netherlands) (R10) supplementedwith 15%L929-conditioned
medium (LCM) for 8–9 days to generate bone marrow-derived macrophages
(BMM), as described previously (Kanters et al., 2003). Cells were treated for
24 hr with 100U/ml IFNa or IFNb.
In Vitro Human Macrophage Culture
Humanmononuclear cells were obtained by apheresis of 23 the blood volume
from healthy volunteers using a Cobe Spectra (CaridianBCT Europe, Zaven-
them, Belgium). Monocytes were subsequently enriched by counter flow
centrifugation using the Elutra Cell Separation System (CaridianBCT) and
were cultured in R10 supplemented with 5 ng/ml M-CSF (Peprotech) for
8 days to generate human macrophages. Cells were treated for 24 hr with
100U/ml human IFNb.
Gene Expression
RNA was isolated from BMM or human macrophages with the High Pure
RNA Isolation Kit (Roche, Basel, Switzerland). 500 ng total RNA was reverse
transcribed using the iScript cDNA Synthesis Kit (BioRad, Veenendaal, The
Netherlands). Quantitative PCR (Q-PCR) was performed using 10 ng cDNA,
300 nM of each primer, and IQ SYBR Green Supermix (BioRad) in a total
volume of 20 ml. Deletion efficiency in BMM of the LysMCre-IFNAR1fl/fl miceCelwas measured by Q-PCR on 25 ng DNA as described before (Kanters et al.,
2003), using primers specifically detecting the floxed and not the deleted
or wild-type IFNAR1 allele. All gene expression levels were corrected for
cyclophilin A as housekeeping gene, and primer sequences are available
upon request.
In Vitro oxLDL and Bead Uptake
BMM untreated or treated for 24 hr with 100U/ml IFNb were incubated for 3 hr
in Optimem-1 with fluorescently labeled latex beads or 25 mg/ml DiI-labeled
oxLDL and were generated through copper oxidation, as described previously
(Kanters et al., 2003). Uptake was assessed by flow cytometry after residual
beads or oxLDL were washed away.
Flow Cytometry
BMM (± 100U/ml IFNb for 24 hr) were stained with antibodies against VLA-4
(PE labeled, Cedarlane, Burlington, Ontario, Canada), Mac1, LFA-1, PSGL1
(all PE labeled, BD PharMingen, Erembodegem, Belgium), CCR2 (Epitomics,
Burlingame, CA), or CCR5 (biotinylated, BD PharMingen), and their mean
fluorescence was measured by FACS analysis. For the CCR2 staining, cells
were permeabilized using Cytoperm Plus Permeabilization Buffer and Perm/
Wash Buffer (both BD PharMingen), and CCR2 antibody was detected using
anti-rabbit IgG FITC (Sigma-Aldrich). CCR5 antibody was detected with
APC-conjugated streptavidin (BD PharMingen).
ELISA
Murine CCL5 secretion from BMM (± 100 U/ml IFNb for 24 hr) was measured
by ELISA using anti-mouse CCL5 (R&D Systems, Abigndon, UK) as coating
antibody and biotinylated anti-mouse CCL5 (R&D Systems) as detection
antibody with mouse CCL5 (Peprotech) as standard. Human CCL5 secretion
in the supernatants from human macrophages (± 100U/ml IFNb for 24 hr)
was measured by commercial ELISA (PBL Interferon Source, New Brunswick,
NJ). Absorbance was measured at 450 nm using a microtiterplate reader
(BioRad, Hercules, CA).
In Vitro Adhesion Assay
A confluent monolayer of bEND5 endothelial cells was grown in fluorescence
96-well microplates (Greiner Bio-one, Frickenhausen, Germany). Triplicate
wells were incubated for 30 min with 105 BMM (pretreated ± 100U/ml IFNb
for 24 hr) that had been fluorescently labeled with a PKH dye according to
themanufacturer’s instructions (Sigma Aldrich, Zwijndrecht, The Netherlands).
Subsequently, the wells were washed three times with R10, and adherent
cells were measured by fluorometry in a Synergy HT microtiter plate reader
(BioTek, Bad Friedrichshall, Germany) at an excitation of 485 nm and an
emission of 520 nm.
In Vivo Leukocyte Adhesion
Apoe/ mice were put on a high-fat diet (0.15% cholesterol, 21% fat,
Altromin) for 6 weeks and during the last 4 days were daily injected sub-
cutaneously with either saline or IFNb (5000 U). Four mice receiving saline
injections and five receiving IFNb injections were cotreatedwith an intravenous
Met-RANTES (50 mg/mouse) injection 30 min before the experiment. After
sedation (intraperitoneal Ketamine/Xylazin) and intravenous rhodamin injec-
tion, the left carotid artery was exposed and three high-power fields (hpf)
near the carotid bifurcation were visualized by epifluorescence microscopy
(Zeiss Axiotech, 203water immersion objective) as described before (Bernha-
gen et al., 2007). Short movies were recorded for each hpf, in which the cells
attaching to the vessel wall were counted by eye.
Collar-Induced Atherosclerosis
Seventeen-week-old male apoe/mice (n = 21) were operated after 3 weeks
of high-fat diet (0.25% cholesterol, 16% fat) to introduce a 2 mm long noncon-
strictive silastic tube around both carotid arteries, as described before (von der
Thu¨sen et al., 2001). During the 24 days postoperation, the high-fat diet was
continued and the mice were treated by daily subcutaneous injection of either
IFNb (5000 U) or saline. Upon sacrifice, the right carotid artery was isolated
and embedded in paraffin. Sections of 5 mm were made, and after every
100 mm, sections were stained with hematoxilin/eosin for lesion area analysis.l Metabolism 12, 142–153, August 4, 2010 ª2010 Elsevier Inc. 151
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Twelve-week-oldmale ldlr/micewere fed a high-fat diet (0.15%cholesterol,
16% fat, Arie Blok, The Netherlands) for 6 weeks in order to induce early
atherogenesis. At this point, daily subcutaneous injections of either IFNb
(5000 U) or saline were started and continued for 3 weeks while the high-fat
diet was continued. Upon sacrifice, the heart and aorta were taken out. The
hearts were cut perpendicular to the heart axis just below the atrial tips. Tissue
was frozen in tissue-tec (Shandon, Veldhoven, The Netherlands) and cut into
sections of 7 mm as described before (Kanters et al., 2003). Serial cross-
sections from every 42 mm were stained with toluidin blue. All lesion areas
were quantified using Adobe Photoshop software. The aortas were snap
frozen and RNA was isolated using the RNeasy Mini Kit (QIAGEN, Venlo,
The Netherlands), including DNase treatment. Gene expression was assessed
by Q-PCR, as described above.
Bone Marrow Transplantation
One week before transplantation, female ldlr/mice were housed in filter-top
cages and provided with acidified water containing neomycin (100mg/l;
GIBCO, Breda, The Netherlands) and polymyxin B sulfate (6 3 104 U/l;
GIBCO). The animals received 2 3 6Gy total body irradiation on two
consecutive days. On the second day, bone marrow was isolated from
6 LysMCre-IFNAR1fl/fl mice (IFNAR1del) and 6 IFNAR1fl/fl littermates
(IFNAR1WT), and 107 cells/mouse were injected intravenously to rescue the
hematopoietic system of the irradiated mice. Four weeks after the transplan-
tation, mice were fed a high-fat diet (0.15% cholesterol, 16% fat, Arie Blok,
The Netherlands) for 11 weeks. After sacrifice, the hearts from the bone
marrow-transplanted mice were taken out, and lesion size in the aortic root
was measured as described above. The lesions were also typed according
to severity as early, moderate, and advanced, as described before (Kanters
et al., 2003).
Mouse Blood Parameters
At several time points during all in vivo atherosclerosis experiments, blood was
drawn from the mice. Plasma lipid levels were monitored enzymatically (Sigma
Aldrich, Zwijndrecht, The Netherlands), and plasma cytokine levels were
measured by flow cytometry using a Cytometric Bead Array kit (BD-PharMin-
gen, San Diego). Plasma CCL5 levels were analyzed by ELISA according to
manufacturer’s instructions (R&D systems). For the bonemarrow-transplanted
mice, leukocytes were counted using a Coulter counter, and blood cell distri-
bution was quantified by flow cytometry after antibody staining with either
Mac1-PE and Gr1-FITC for macrophages and granulocytes or 6B2-PE and
KT3-FITC for B and T cells (BD-PharMingen, Erembodegem, Belgium).
Immunohistochemical Staining
Lesions from the aortic root were fixed in acetone and incubated with anti-
bodies against macrophages (MOMA-2, a gift from G. Kraal), granulocytes
(NIMP, directed against Ly6G, a gift from P. Heeringa), T cells (KT3, directed
against CD3, a gift fromG. Kraal), and proliferating cells (Ki-67, Dako, Glostrup,
Denmark). Apoptotic cells in the plaques were stained by the TUNEL staining
(Roche Diagnostics, Mannheim, Germany) according to the manufacturer’s
protocol. Necrotic areas were analyzed on toluidin blue-stained sections
and identified by the presence of pyknosis, karyorrhexis, or complete absence
of nuclei.
Human Plaque Transcriptomics
Microarray analysis was performed on RNA isolated from 44 (22 stable and
22 ruptured) human carotid plaque specimens using Illumina Human
Sentrix-8 V2.0 BeadChip technology to detect differential expression. For
pathway analysis, we used the Ingenuity Pathway Analysis (Ingenuity Systems,
http://www.ingenuity.com) system. Further details are given in the
Supplemental Experimental Procedures.
Statistical Analysis
The statistical analyses were performed using Graphpad Prism (Graphpad
Software). Differences between two groups were evaluated using a t test
unless stated otherwise. Values are represented as mean ± SEM. A p value
of less than .05 was considered to be statistically significant. All mouse data
passed a normality test.152 Cell Metabolism 12, 142–153, August 4, 2010 ª2010 Elsevier IncSUPPLEMENTAL INFORMATION
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